Reckitt Benckiser Group plc Sponsored ADR (RBGLY)
Exclusive: Reckitt talks exclusively to Advent on Essential Home sale, sources say
Britain's Reckitt is talking exclusively to private equity firm Advent International over a sale of the consumer goods group's Essential Home business, two sources with direct knowledge of the matter told Reuters.
Is Reckitt Benckiser Group (RBGLY) Outperforming Other Consumer Staples Stocks This Year?
Here is how Reckitt Benckiser Group PLC (RBGLY) and Reeds (REED) have performed compared to their sector so far this year.
Lysol Maker Reckitt Confident of Mitigating Tariff Impact
The Lysol maker confirmed its 2025 guidance as it reported comparable sales growth for the first quarter.
Reckitt Benckiser Group (RBGLY) Upgraded to Strong Buy: Here's What You Should Know
Reckitt Benckiser Group (RBGLY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You Looking for a Top Momentum Pick? Why Reckitt Benckiser Group PLC (RBGLY) is a Great Choice
Does Reckitt Benckiser Group PLC (RBGLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Reckitt says US court grants new trial in preterm formula case
Reckitt said on Friday a circuit court in the United States had ruled that a new trial could be sought by plaintiffs in a case that accused the London-listed firm and Abbott of failing to warn of the risks of premature-infant formulas.
Reckitt misses fourth-quarter sales expectations
Reckitt , the maker of Dettol cleaning products and Strepsils throat lozenges, missed expectations for fourth-quarter like-for-like net sales, posting on Thursday a 4.6% rise.
Reckitt Benckiser ups dividend as profit slips on reshuffle
Reckitt Benckiser Group PLC has upped its dividend after a drop in profit last year as efforts continued to revamp the consumer goods business. Operating profit fell 4.2% to £2.43 billion in the year to December 31, as revenue slipped 3.0% to £14.17 billion on an international financial reporting standards basis.
Reckitt Benckiser Group: New Bull Run Initiated
Reckitt has shown a medium-term uptrend since April 2024, outperforming peers, but litigation risks from Mead Johnson remain substantial, making the stock a hold. Reckitt's strategic focus on high-growth, high-margin brands and potential divestitures could drive future revenue and earnings growth, despite current sales declines. The company's dividend history is strong, with a 22-year streak of no cuts, but future increases are likely modest due to a high payout ratio.
Reckitt Benckiser: Still Cheap On Nutrition Woes
Reckitt Benckiser shareholders have had a tough year, with the stock underperforming global staples by around 17 points since my last article in January. Uncertainty surrounding the cost of litigation relating to its infant formula business has driven much of that. Reckitt maintains a good underlying business, and Nutrition is only 10% of earnings. The stock trades for just 15x EPS, representing a circa 25% discount to its long-run average and a 40% discount compared to select peers.
Reckitt Benckiser adds tier-one execs to board
Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) bolstered its boardroom, adding more c-suite expertise in non-executive positions. Bacardi chief executive Mahesh Madhavan is taking a seat as a non-executive director, whilst ex-Merck chief exec and chair Stefan Oschmann similarly joins as a NED.
Reckitt Benckiser shares jump after clearance in latest baby formula trial
Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) shares climbed over 10% on Friday morning after the consumer group was cleared in the latest trial on disease risks related to baby formula. A court in Missouri on Thursday rejected claims that formula made by Reckitts' Mead Johnson division, alongside Abbott, caused inflammation of the bowel, or necrotizing enterocolitis, which can require invasive surgery.
